SAN DIEGO, Jan. 12, 2021 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) has been named a winner of
Business Intelligence Group's 2021 BIG Innovation Awards for
outstanding innovation with first-in-class non-hormonal
prescription contraceptive vaginal gel, Phexxi® (lactic acid,
citric acid and potassium bitartrate). This annual business awards
program recognizes organizations, products, and people that are
bringing new ideas to life in innovative ways.
"As a female-led, female-focused company, we put women's needs
first and innovate for them. We know firsthand about the serious
responsibility and impact of family planning," said Saundra Pelletier, Chief Executive Officer,
Evofem Biosciences. "Despite the 18 categories of contraception,
nearly half of all U.S. pregnancies are still unplanned. Women need
options they can and will use, including on-demand hormone-free
prescription birth control.
"Innovation is our opportunity to effect real change in women's
lives. We appreciate Business Intelligence Group for recognizing
our efforts," continued Pelletier. "Poverty elimination is
profoundly impacted when a woman can choose when, if and how often
she has children, and the best way to assist her is with innovation
in birth control options."
Phexxi is designed to be used immediately before or up to an
hour before intercourse. It was approved by the U.S. Food and Drug
Administration in May 2020, and is now available in the
U.S. by prescription. Phexxi works to maintain vaginal pH, which
reduces sperm mobility, lowering the chance of sperm reaching the
egg, and is the first non-hormonal contraceptive method created for
women in decades.
Organizations from across the globe submitted their recent
innovations for consideration in the BIG Innovation Awards.
Nominations were judged by a select group of business leaders and
executives who volunteered their time and expertise to score
submissions.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is a commercial-stage biopharmaceutical company
committed to developing and commercializing innovative products to
address unmet needs in women's sexual and reproductive health,
including hormone-free, woman-controlled contraception and
protection from certain sexually transmitted infections (STIs). The
Company's first commercial product, Phexxi® (lactic acid, citric
acid and potassium bitartrate), is the first and only hormone-free,
prescription vaginal gel approved in the United
States for the prevention of pregnancy. The Company is
evaluating EVO100 in a Phase 3 clinical
trial, 'EVOGUARD,' for the prevention of urogenital
Chlamydia trachomatis and Neisseria
gonorrhoeae infection in women. For more information,
please visit www.evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences,
Inc.
About PHEXXI®
Phexxi® (lactic acid, citric acid,
and potassium bitartrate) is a prescription vaginal gel used to
prevent pregnancy in females who choose to use an on-demand method
of birth control. Phexxi® is only effective when used
immediately before (or up to one hour before) each
act of vaginal sex. Phexxi® is not effective when used after
vaginal sex.
IMPORTANT SAFETY INFORMATION
WHAT ARE THE POSSIBLE SIDE EFFECTS OF PHEXXI® (lactic
acid, citric acid, and potassium bitartrate) vaginal gel 1.8%, 1%,
0.4%?
If you have had a history of repeated urinary tract infections
or other urinary tract problems, avoid Phexxi®.
The most common side effects were vaginal
burning, vaginal itching, vaginal yeast infection, urinary tract
infection, vaginal area discomfort, bacterial vaginosis, and
vaginal discharge. Women also reported genital discomfort, pain
while urinating, and vaginal pain. Some male partners reported
genital discomfort.
What else should I know about using Phexxi®?
Phexxi® does not protect against any sexually transmitted
diseases, including HIV. Avoid using Phexxi® with a vaginal
ring.
Contact your healthcare provider if you are experiencing severe
genital irritation or discomfort or urinary tract symptoms. Avoid
Phexxi® if you or your sexual partner is allergic to lactic
acid, citric acid, potassium bitartrate, or any of the ingredients
in Phexxi®. Stop using Phexxi® if you develop an allergic
reaction.
Please see full Prescribing
Information for Phexxi®,
including Patient Information.
Please report side effects by contacting Evofem Biosciences
toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088
or www.fda.gov/medwatch.
Forward Looking Statements
This press release includes "forward-looking statements," within
the meaning of the safe harbor for forward-looking statements
provided by Section 21E of the Securities Exchange Act of 1934, as
amended; and the Private Securities Litigation Reform Act of 1995.
Various factors could cause actual results to differ materially
from those discussed or implied in the forward-looking statements,
and you are cautioned not to place undue reliance on these
forward-looking statements, which are current only as of the date
of this press release. Each of these forward-looking statements
involves risks and uncertainties. Important factors that could
cause actual results to differ materially from those discussed or
implied in the forward-looking statements, or that could impair the
value of Evofem Biosciences' assets and business, are disclosed in
Evofem's SEC filings, including its Annual Report on Form 10-K for
the year ended December 31, 2019
filed with the SEC on March 12, 2020,
its Current Report on Form 8-K filed with the SEC on June 2, 2020, and its Quarterly Report on Form
10-Q for the quarter ended September 30,
2020 filed with the SEC on November
9, 2020. All forward-looking statements are expressly
qualified in their entirety by such factors. Evofem does not
undertake any duty to update any forward-looking statement except
as required by law.
About Business Intelligence Group
The Business Intelligence Group was founded with the mission of
recognizing true talent and superior performance in the business
world. Unlike other industry award programs, these programs are
judged by business executives having experience and knowledge. The
organization's proprietary and unique scoring system selectively
measures performance across multiple business domains and rewards
those companies whose achievements stand above those of their
peers.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
Media Contact
Ellen
Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490-3248
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-wins-business-intelligence-groups-big-innovation-award-2021-301205794.html
SOURCE Evofem Biosciences, Inc.